

Overview

Useful For

Monitoring serum gabapentin concentrations

Assessing compliance

Adjusting dosage in patients

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

NY State Available

Yes

Specimen

Specimen Type

Serum Red

Specimen Required

Collection Container/Tube: Red top (serum gel/SST is not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.
2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-[Neurology Specialty Testing Client Test Request](#) (T732)

-[Therapeutics Test Request](#) (T831)

Specimen Minimum Volume

0.2 mL

Reject Due To

| | |
|-----------------|----|
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |

Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---------------|--------------------------|---------|-------------------|
| Serum Red | Refrigerated (preferred) | 28 days | |
| | Ambient | 28 days | |
| | Frozen | 28 days | |

Clinical & Interpretive

Clinical Information

Gabapentin is an antiepileptic drug that is effective in treating seizures, neuropathies, and a variety of neurological and psychological maladies. Although designed as a gamma-aminobutyric acid (GABA) analogue, gabapentin does not bind to GABA receptors, nor does it affect the neuronal uptake or degradation of GABA. In fact, the precise mechanism by which it exerts its analgesic and anticonvulsant effects is unknown.

After oral administration and absorption, gabapentin circulates essentially unbound to serum proteins. In addition, gabapentin does not undergo hepatic metabolism, unlike most other antiepileptic drugs, and is eliminated almost entirely by renal excretion with a clearance that approximates the glomerular filtration rate. The elimination half-life is 5 to 7 hours in patients with normal kidney function.

Since gabapentin does not bind to serum proteins, it does not exhibit pharmacokinetic variability and interactions with other highly protein-bound medications (eg, phenytoin). In addition, the lack of hepatic metabolism eliminates the interactions with other hepatically cleared medications, which can induce/inhibit hepatic drug metabolizing enzyme systems (eg, cytochrome P450 enzymes). Therefore, gabapentin serum concentration is not changed following the addition or discontinuation of other common anticonvulsants (ie, phenobarbital, phenytoin, carbamazepine, or valproic acid), nor are their serum concentrations altered upon the addition or discontinuation of gabapentin.

In general, adverse effects with gabapentin are infrequent and usually resolve with continued treatment. The most common side effects include somnolence, dizziness, ataxia, and fatigue. Experience to date indicated that gabapentin is safe and relatively nontoxic.

Reference Values

2.0-20.0 mcg/mL

Toxic Range: > or =25.0 mcg/mL

Interpretation

Therapeutic ranges are based on specimens collected immediately before the next dose (ie, trough).

Most epileptic patients show a response to the drug when the trough concentration is in the range of 2 to 20 mcg/mL. Therapeutic drug monitoring may be useful due to inter-individual variation in pharmacokinetics and dose-dependent bioavailability; specimens for measurements should be collected before the morning dose since the short half-life may affect the interpretation of the concentration.

Cautions

This test cannot be performed on whole blood. Serum must be separated from cells within 2 hours of collection.

Specimens collected in serum gel tubes (serum separator tubes) are not acceptable as the drug/analyte can absorb on the gel barrier and lead to falsely decreased concentrations.

Clinical Reference

1. Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
2. Patsalos PN, Berry DJ, Bourgeois BF, et al: Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 Jul;49(7):1239-1276
3. Johannessen SI, Tomson T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinetics. 2006;45(11):1061-1075

Performance**Method Description**

Gabapentin and the internal standard are separated from other serum constituents with analysis on a tandem mass spectrometer equipped with an electrospray ion source using multiple reaction monitoring. (Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Monday through Saturday

Report Available

Same day/1 to 2 days

Specimen Retention Time

2 weeks

Performing Laboratory Location

Rochester

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.

- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80171

LOINC® Information

| Test ID | Test Order Name | Order LOINC® Value |
|---------|-----------------|--------------------|
| GABA | Gabapentin, S | 9738-6 |

| Result ID | Test Result Name | Result LOINC® Value |
|-----------|------------------|---------------------|
| 80826 | Gabapentin, S | 9738-6 |